Back to Search Start Over

Establishment of Patient-derived Preclinical Models for Invasive Papillary Cholangiocarcinoma.

Authors :
Mwesige B
Lee MR
Lee YS
Han NY
Im JE
Kim JK
Choi SI
Hong EK
Jeon AR
Park SJ
Woo SM
Kim YH
Source :
Anticancer research [Anticancer Res] 2022 Jan; Vol. 42 (1), pp. 599-608.
Publication Year :
2022

Abstract

Background/aim: Invasive papillary cholangio-carcinoma (IPC) is a minor subtype of extrahepatic cholangiocarcinoma. However, its etiology and characteristics remain unknown because of the unavailability of in vitro and in vivo models. We aimed to establish a novel preclinical model for translational research of IPC.<br />Materials and Methods: A patient-derived xenograft (PDX) was engrafted in NOG mice and the cell line National Cancer Center human IPC (NCChIPC) was subsequently established from the PDX tumors. Immunohistochemistry and RNA-sequencing were used to determine the retention of original characteristics of patient tissues.<br />Results: PDX tumors showed successful amplification, and the NCChIPC-derived xenograft largely retained the histopathological features of the original tumor with CK19, MUC1 and MUC5AC expression. Transcriptome analysis showed a high correlation between patient and preclinical models. Additionally, anticancer drugs response was analyzed in the NCChIPC PDX.<br />Conclusion: These novel preclinical models here will help elucidate IPC etiology and facilitate translational research.<br /> (Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)

Details

Language :
English
ISSN :
1791-7530
Volume :
42
Issue :
1
Database :
MEDLINE
Journal :
Anticancer research
Publication Type :
Academic Journal
Accession number :
34969769
Full Text :
https://doi.org/10.21873/anticanres.15517